# ALNYLAM PHARMACEUTICALS, INC. (ALNY) FY2026 Q2 Balance Sheet

- Company: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-30, accession number 0001178670-26-000062
- Page: https://plicit.ai/financials/alny/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/alny-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 5,558,769,000 US dollars
- **Current assets**: 4,620,172,000 US dollars
- **Non-current assets**: 938,597,000 US dollars
- **Liabilities**: 4,204,651,000 US dollars
- **Current liabilities**: 1,512,513,000 US dollars
- **Non-current liabilities**: 2,692,138,000 US dollars
- **Equity**: 1,354,118,000 US dollars
- **Cash and cash equivalents**: 1,708,318,000 US dollars
- **Marketable debt securities**: 1,599,829,000 US dollars
- **Accounts receivable, net**: 912,739,000 US dollars
- **Prepaid expenses and other current assets**: 302,176,000 US dollars
- **Inventory**: 97,110,000 US dollars
- **Property, plant and equipment, net**: 554,143,000 US dollars
- **Operating lease right-of-use assets**: 183,359,000 US dollars
- **Deferred tax assets**: 113,792,000 US dollars
- **Other assets**: 65,132,000 US dollars
- **Restricted investments**: 22,171,000 US dollars
- **Accrued expenses**: 1,095,980,000 US dollars
- **Liabilities related to the sale of future royalties and development funding**: 258,570,000 US dollars
- **Accounts payable**: 108,016,000 US dollars
- **Operating lease liabilities**: 45,933,000 US dollars
- **Deferred revenue**: 4,014,000 US dollars
- **Liabilities related to the sale of future royalties and development funding, net of current portion**: 1,461,510,000 US dollars
- **Convertible debt**: 1,010,981,000 US dollars
- **Operating lease liabilities, net of current portion**: 210,495,000 US dollars
- **Other liabilities**: 9,152,000 US dollars
- **Additional paid-in capital**: 7,716,958,000 US dollars
- **Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025**: 1,337,000 US dollars
- **Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025**: 0 US dollars
- **Accumulated deficit**: negative 6,332,039,000 US dollars
- **Accumulated other comprehensive loss**: negative 32,138,000 US dollars
- **Gross equity (calculated)**: 7,718,295,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.